Go or no go? Key FDA decisions for Argenx and Regeneron

The first month of summer brings with it several key Pdufa decisions including one for Argenx, which is going for convenience with its subcutaneous version of Vyvgart in generalised myasthenia gravis. UCB’s competing project rozanolixizumab is also due a decision soon, but that agent needs to be infused, and has a poor side effect profile.